• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.《使用药物警戒中的个体病例安全报告进行药物安全性信号检测的不适当性分析报告(READUS-PV):解释与说明》。
Drug Saf. 2024 Jun;47(6):585-599. doi: 10.1007/s40264-024-01423-7. Epub 2024 May 7.
2
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.使用个体病例安全报告在药物警戒中进行药物安全性信号检测的不均衡分析报告:方法学开发与声明。
Drug Saf. 2024 Jun;47(6):575-584. doi: 10.1007/s40264-024-01421-9. Epub 2024 May 7.
3
A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases.一项荟萃流行病学研究发现,药物警戒数据库中信号检测的不均衡分析缺乏透明度和报告质量较差。
J Clin Epidemiol. 2021 Nov;139:191-198. doi: 10.1016/j.jclinepi.2021.07.014. Epub 2021 Jul 27.
4
The evolving role of disproportionality analysis in pharmacovigilance.药物警戒中比例失衡分析的作用演变。
Expert Opin Drug Saf. 2024 Aug;23(8):981-994. doi: 10.1080/14740338.2024.2368817. Epub 2024 Jun 24.
5
High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study.在使用不成比例分析来检测安全信号的药物警戒研究中发现自旋的高患病率:一项元流行病学研究。
J Clin Epidemiol. 2021 Oct;138:73-79. doi: 10.1016/j.jclinepi.2021.06.022. Epub 2021 Jun 26.
6
Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.药品不良反应信号检测中小数据库或子数据集的不均衡性分析:限制假阳性关联的建议。
Drug Saf. 2020 May;43(5):479-487. doi: 10.1007/s40264-020-00911-w.
7
vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use.药物警戒中用于统计信号检测的vigiRank:前瞻性实际应用的初步结果。
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):1006-1010. doi: 10.1002/pds.4247. Epub 2017 Jun 27.
8
Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.从荟萃分析和药物警戒不稳定性分析中获得的药物不良反应风险在大多数情况下是相关的。
J Clin Epidemiol. 2021 Jun;134:14-21. doi: 10.1016/j.jclinepi.2021.01.015. Epub 2021 Jan 26.
9
Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.统计信号检测中的风险因素考虑:使用亚组不均衡性揭示 VigiBase 中药物不良反应的风险人群。
Drug Saf. 2020 Oct;43(10):999-1009. doi: 10.1007/s40264-020-00957-w.
10
Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.因果关系评估对自动检测安全信号的贡献:用法语药物警戒数据库举例。
Drug Saf. 2020 Mar;43(3):243-253. doi: 10.1007/s40264-019-00887-2.

引用本文的文献

1
Emerging causes of anticancer therapies-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: evidence from disproportionality analysis of the FDA adverse event reporting system.抗癌疗法诱发史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的新病因:来自美国食品药品监督管理局不良事件报告系统不成比例分析的证据
Front Immunol. 2025 Aug 27;16:1646038. doi: 10.3389/fimmu.2025.1646038. eCollection 2025.
2
Exploring the Reliability of Detecting Drug-Drug Interactions that Increase the Risk of Gestational Diabetes in Adverse Event Reporting Systems.在不良事件报告系统中探索检测增加妊娠期糖尿病风险的药物相互作用的可靠性。
Drug Saf. 2025 Sep 2. doi: 10.1007/s40264-025-01607-9.
3
Complexity of interstitial lung disease disproportionality signal analysis in pharmacovigilance databases.药物警戒数据库中间质性肺疾病不成比例信号分析的复杂性
EClinicalMedicine. 2025 Aug 21;87:103450. doi: 10.1016/j.eclinm.2025.103450. eCollection 2025 Sep.
4
Response to "complexity of interstitial lung disease disproportionality signal analysis in pharmacovigilance databases".对“药物警戒数据库中间质性肺疾病不均衡信号分析的复杂性”的回应
EClinicalMedicine. 2025 Aug 20;87:103451. doi: 10.1016/j.eclinm.2025.103451. eCollection 2025 Sep.
5
Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database.帕博利珠单抗治疗子宫内膜癌的真实世界药物不良反应研究:来自FAERS数据库的见解
Front Pharmacol. 2025 Aug 15;16:1622339. doi: 10.3389/fphar.2025.1622339. eCollection 2025.
6
A comprehensive study on drug-related Raynaud's phenomenon based on the FDA adverse event reporting system.基于美国食品药品监督管理局不良事件报告系统的药物相关性雷诺现象综合研究。
Sci Rep. 2025 Sep 1;15(1):32059. doi: 10.1038/s41598-025-17182-z.
7
Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess.非奈利酮不良反应的特征分析:来自世界卫生组织药物不良反应数据库(WHO-VigiAccess)的深入分析
Front Pharmacol. 2025 Aug 7;16:1545148. doi: 10.3389/fphar.2025.1545148. eCollection 2025.
8
Meningioma in users of progestogen contraceptives: a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS).使用孕激素避孕药的女性患脑膜瘤情况:对美国食品药品监督管理局不良事件报告系统(FAERS)的不成比例性分析
Eur J Clin Pharmacol. 2025 Aug 18. doi: 10.1007/s00228-025-03900-z.
9
Response to Comment on: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data.对《与胰高血糖素样肽-1受体激动剂相关的男性性功能障碍:对美国食品药品监督管理局不良事件报告系统(FAERS)数据的横断面分析》评论的回应
Int J Impot Res. 2025 Aug 7. doi: 10.1038/s41443-025-01143-1.
10
Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports.5α还原酶抑制剂非那雄胺相关的自杀风险:来自美国食品药品监督管理局不良事件报告的真实世界数据评估
Pharmaceuticals (Basel). 2025 Jun 25;18(7):957. doi: 10.3390/ph18070957.

本文引用的文献

1
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.使用个体病例安全报告在药物警戒中进行药物安全性信号检测的不均衡分析报告:方法学开发与声明。
Drug Saf. 2024 Jun;47(6):575-584. doi: 10.1007/s40264-024-01421-9. Epub 2024 May 7.
2
New Adverse Drug Reaction Signals from 2017 to 2021-Genuine Alerts or False Alarms?2017年至2021年新的药品不良反应信号——真实警报还是虚惊一场?
Pharmacy (Basel). 2024 Feb 10;12(1):33. doi: 10.3390/pharmacy12010033.
3
Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network Study.利用常规健康数据的分析支持药物警戒信号验证和优先级排序:EHDEN 网络研究的经验教训。
Drug Saf. 2023 Dec;46(12):1335-1352. doi: 10.1007/s40264-023-01353-w. Epub 2023 Oct 7.
4
Challenges and Opportunities in Accessing and Analysing FAERS Data: A Call Towards a Collaborative Approach.获取和分析药品不良反应事件报告系统(FAERS)数据的挑战与机遇:呼吁采用协作方法
Drug Saf. 2023 Oct;46(10):921-926. doi: 10.1007/s40264-023-01345-w. Epub 2023 Aug 31.
5
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study.绘制评估和提高已发布比例失调信号有效性的策略图:一项元研究。
Drug Saf. 2023 Sep;46(9):857-866. doi: 10.1007/s40264-023-01329-w. Epub 2023 Jul 8.
6
Factors Associated with Underreporting of Adverse Drug Reactions by Health Care Professionals: A Systematic Review Update.与医疗保健专业人员报告药物不良反应不足相关的因素:系统评价更新。
Drug Saf. 2023 Jul;46(7):625-636. doi: 10.1007/s40264-023-01302-7. Epub 2023 Jun 6.
7
Interpretation of Pharmacovigilance Disproportionality Analyses.药物警戒不均衡性分析的解读
Clin Pharmacol Ther. 2023 Oct;114(4):745-746. doi: 10.1002/cpt.2951. Epub 2023 May 30.
8
Considerations on the use of different comparators in pharmacovigilance: A methodological review.药物警戒中不同对照的使用考量:方法学综述。
Br J Clin Pharmacol. 2023 Sep;89(9):2671-2676. doi: 10.1111/bcp.15802. Epub 2023 Jun 8.
9
Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk.识别有风险的安全亚组:评估统计警报和患者亚组风险之间的一致性。
Drug Saf. 2023 Jun;46(6):601-614. doi: 10.1007/s40264-023-01306-3. Epub 2023 May 2.
10
Investigating the link between drug consumption and adverse events reporting in France.调查法国药物使用与不良事件报告之间的联系。
Fundam Clin Pharmacol. 2023 Aug;37(4):879-882. doi: 10.1111/fcp.12893. Epub 2023 Mar 17.

《使用药物警戒中的个体病例安全报告进行药物安全性信号检测的不适当性分析报告(READUS-PV):解释与说明》。

The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.

机构信息

Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.

Université de Bordeaux, INSERM, BPH, Team AHeaD, U1219, 33000, Bordeaux, France.

出版信息

Drug Saf. 2024 Jun;47(6):585-599. doi: 10.1007/s40264-024-01423-7. Epub 2024 May 7.

DOI:10.1007/s40264-024-01423-7
PMID:38713347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11116264/
Abstract

In pharmacovigilance, disproportionality analyses based on individual case safety reports are widely used to detect safety signals. Unfortunately, publishing disproportionality analyses lacks specific guidelines, often leading to incomplete and ambiguous reporting, and carries the risk of incorrect conclusions when data are not placed in the correct context. The REporting of A Disproportionality analysis for drUg Safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV) statement was developed to address this issue by promoting transparent and comprehensive reporting of disproportionality studies. While the statement paper explains in greater detail the procedure followed to develop these guidelines, with this explanation paper we present the 14 items retained for READUS-PV guidelines, together with an in-depth explanation of their rationale and bullet points to illustrate their practical implementation. Our primary objective is to foster the adoption of the READUS-PV guidelines among authors, editors, peer reviewers, and readers of disproportionality analyses. Enhancing transparency, completeness, and accuracy of reporting, as well as proper interpretation of their results, READUS-PV guidelines will ultimately facilitate evidence-based decision making in pharmacovigilance.

摘要

在药物警戒中,基于个体病例安全报告的比例失调分析被广泛用于检测安全信号。不幸的是,发表比例失调分析缺乏具体的指导方针,往往导致报告不完整和模糊,并在数据没有置于正确的背景下时存在错误结论的风险。《使用个体病例安全报告进行药物警戒中药物安全性信号检测的比例失调分析报告(READUS-PV)声明》的制定是为了解决这个问题,通过促进比例失调研究的透明和全面报告。虽然声明文件更详细地解释了制定这些指南所遵循的程序,但通过这份解释文件,我们提出了 READUS-PV 指南保留的 14 项内容,以及对其基本原理和要点的深入解释,以说明其实际实施情况。我们的主要目标是促进作者、编辑、同行评审员和比例失调分析读者采用 READUS-PV 指南。提高报告的透明度、完整性和准确性,以及正确解释其结果,READUS-PV 指南最终将有助于药物警戒中的循证决策。